Although HIFs are associated with increased drug resistance, the first generation of HIF-2α inhibitors, such as TC-S 7009 or PT-2399, were tested in preclinical studies in ccRCC xenografts and in human ccRCC cell lines [23,159]. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.